Mouse monoclonal antibody raised against full length recombinant human CDKN1A.
Recombinant protein corresponding to full length human CDKN1A.
Theoretical MW (kDa):
This monoclonal antibody is highly specific to CDKN1A and shows no cross-reaction with other closely related mitotic inhibitors.
Protein A/G purification
Flow Cytometry (0.5-1 ug/106 cells in 0.1 mL) Immunofluorescence (1-2 ug/mL) Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (2-4 ug/mL) Western Blot (1-2 ug/mL) The optimal working dilution should be determined by the end user.
In 10 mM PBS (0.05% BSA, 0.05% sodium azide).
Store at 4°C.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported. [provided by RefSeq
CDK-interaction protein 1,DNA synthesis inhibitor,OTTHUMP00000016298,cyclin-dependent kinase inhibitor 1A,melanoma differentiation associated protein 6,wild-type p53-activated fragment 1